GlaxoSmithKline and partner Innoviva are seeking an expansion to the US label of their Trelegy Ellipta lung drug.
COPD drug was approved in US in September.
AZ taking on rivals from GSK and Teva.
Hikma to give up date in Q1 next year.
GSK looks to build on mepolizumab’s success in asthma
AstraZeneca is planning filings of its chronic obstructive pulmonary disease drug Bevespi Aerosphere in China and Japan, based
EU regulators also backed Trelegy
AstraZeneca has signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.